Rep. Thomas Kean (R-NJ) Sells Shares of Becton, Dickinson
U.S. Representative Thomas Kean disclosed selling Becton, Dickinson shares valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Thomas Kean (R-NJ)
- Status:
- Member — House
- State/District:
- NJ-7
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 19, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Becton, Dickinson and Company ($BDX) | Sell | May 21, 2026 | $1,001 - $15,000 |
Key Points
- Thomas Kean, a U.S. House member, sold Becton, Dickinson shares valued between $1,001 and $15,000 on May 21, 2026.
- Becton, Dickinson's stock trades at $143.98, with a market cap of $39.67 billion and a forward P/E of 10.75.
- Insiders, including CEO Thomas Polen, also traded shares recently, while analysts set varied price targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
U.S. Representative Thomas Kean recently disclosed a sale of shares in Becton, Dickinson and Company (NYSE: BDX). The transaction, dated May 21, 2026, was valued between $1,001 and $15,000. This is part of periodic reports filed under the STOCK Act, which are released after the trade occurs.
Thomas Kean vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Becton, Dickinson and Company Stock Down 20.2%
Shares of NYSE:BDX were trading around $143.98. The company boasts a market cap of approximately $39.67 billion. Its forward P/E ratio stands at 10.75, suggesting some growth expectations. The stock has experienced a 52-week low of $127.59 and a high of $187.35. Becton, Dickinson's beta is a low 0.278, indicating less volatility compared to the market. The company maintains a current ratio of 0.942 and a quick ratio of 0.355, with a debt-to-equity ratio of 71.599.
$BDX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Becton, Dickinson reported revenue of $22.23 billion, reflecting a growth rate of 5.2%. The company's net margin is 5.12%, with a return on equity of 6.67%. Earnings per share came in at $5.73. The next earnings announcement is expected on August 6, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Dividend
The company offers a dividend rate of $4.20, yielding 2.89%. The payout ratio is 72.95%, indicating a significant portion of earnings returned to shareholders.
Insider Buying and Selling at Becton, Dickinson and Company
Several insiders have been active in trading Becton, Dickinson shares. Michael David Garrison, EVP & President of Medical Essentials & BioPharma, sold 1,100 shares at an average price of $151.48 on June 10, 2026, under a pre-planned Rule 10b5-1. On June 1, 2026, Chairman, CEO, and President Thomas Polen Jr. sold shares at prices ranging from $126.16 to $146.35, with some transactions planned and others not.
Analysts Set New Price Targets
On May 11, 2026, Barclays maintained a 'buy' rating on Becton, Dickinson with a price target of $204. Wells Fargo, on May 8, 2026, reiterated a 'hold' rating, setting a target at $161. Meanwhile, TD Cowen and Piper Sandler also maintained 'hold' ratings with targets of $163 and $159, respectively. The consensus among 13 analysts is a 'buy', with an average target price of $180.69.
About Becton, Dickinson
Becton, Dickinson and Company, headquartered in Franklin Lakes, New Jersey, is a global leader in the healthcare sector. The company develops, manufactures, and sells a wide array of medical supplies and devices, laboratory equipment, and diagnostic products. Its products serve healthcare institutions, physicians, and the pharmaceutical industry, among others. Founded in 1897, Becton, Dickinson operates through various segments, including Medical Essentials and BioPharma Systems, and employs around 60,000 people.
Bottom Line
Thomas Kean's sale of Becton, Dickinson shares is a reminder of the ongoing interest in the company's stock by various stakeholders. Investors keep an eye on such transactions for insights, even though 13F filings and insider reports are backward-looking and do not necessarily reflect current positions. With its strong market presence and strategic initiatives, Becton, Dickinson remains a company to watch.
Get Becton, Dickinson and Company alerts
New 13F filings, insider trades, and analyst moves on $BDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.